Abstract
Stroke is the 4th leading cause of death and disability in adults in the USA. However, in the majority of patients, the detrimental effects of an ischemic insult go untreated because of the lack of efficacious neuroprotective compounds. Using naturally occurring compounds as a building block to create efficacious neuroprotective compounds that cross the blood brain barrier may eventually benefit the stroke patients. However, historically, the development of novel compounds has been fraught with problems including lack of significant pleiotropic activity, inability to effectively cross the blood brain barrier and poor bioavailability. This article details, in a stepwise manner, the synthesis and in vitro screening steps used to produce new flavonoids that have increased neuroprotective activity compared to the parent compound fisetin. Moreover, as a preliminary de-risking step, select compounds have been screened in a transfected Madin Darby canine kidney cell assay as a measure of blood brain barrier penetration. Initial de-risking steps have allowed us to identify a series of BBB-penetrating neuroprotective candidates for further development.
Keywords: Flavonoid, chalcone, flavone, MDCK, RSCEM, clinical function, screening, pleiotropic, stroke, blood brain barrier.
Current Pharmaceutical Design
Title:A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke
Volume: 18 Issue: 25
Author(s): Paul A. Lapchak
Affiliation:
Keywords: Flavonoid, chalcone, flavone, MDCK, RSCEM, clinical function, screening, pleiotropic, stroke, blood brain barrier.
Abstract: Stroke is the 4th leading cause of death and disability in adults in the USA. However, in the majority of patients, the detrimental effects of an ischemic insult go untreated because of the lack of efficacious neuroprotective compounds. Using naturally occurring compounds as a building block to create efficacious neuroprotective compounds that cross the blood brain barrier may eventually benefit the stroke patients. However, historically, the development of novel compounds has been fraught with problems including lack of significant pleiotropic activity, inability to effectively cross the blood brain barrier and poor bioavailability. This article details, in a stepwise manner, the synthesis and in vitro screening steps used to produce new flavonoids that have increased neuroprotective activity compared to the parent compound fisetin. Moreover, as a preliminary de-risking step, select compounds have been screened in a transfected Madin Darby canine kidney cell assay as a measure of blood brain barrier penetration. Initial de-risking steps have allowed us to identify a series of BBB-penetrating neuroprotective candidates for further development.
Export Options
About this article
Cite this article as:
A. Lapchak Paul, A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke, Current Pharmaceutical Design 2012; 18 (25) . https://dx.doi.org/10.2174/138161212802002652
DOI https://dx.doi.org/10.2174/138161212802002652 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Red Wine Consumption and Prevention of Atherosclerosis: An In Vitro Model Using Human Peripheral Blood Mononuclear Cells
Current Pharmaceutical Design Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI
Current Pharmaceutical Biotechnology <i>Panax notoginseng</i> Saponins Promote Cell Death and Chemosensitivity in Pancreatic Cancer through the Apoptosis and Autophagy Pathways
Anti-Cancer Agents in Medicinal Chemistry Technological Innovations in Magnetic Resonance for Early Detection of Cardiovascular Diseases
Current Pharmaceutical Design Medical Devices for Telemedicine and Home Care Applications
Recent Patents on Biomedical Engineering (Discontinued) Can Life Before Birth Affect Health Ever After?
Current Women`s Health Reviews Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Statins in Stable Angina Pectoris
Current Pharmaceutical Design Genetics and Heart Failure: A Concise Guide for the Clinician
Current Cardiology Reviews HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions
Current Diabetes Reviews Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Brain Oxidative Markers in Stress: Possible New Drug Targets Against Neuroinflammation
Current Neuropharmacology Meet Our Editorial Board Member
Current Cardiology Reviews Cholesterol and Alzheimers Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors
Current Drug Targets Effects of Verbascoside Administration on the Blood Parameters and Oxidative Status in Jennies and Their Suckling Foals: Potential Improvement of Milk for Human Use
Endocrine, Metabolic & Immune Disorders - Drug Targets The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment
Current Pharmaceutical Design What’s Old is New Again – A Review of the Current Evidence of Colchicine in Cardiovascular Medicine
Current Cardiology Reviews Recent Advances and Patents on Novel Devices for Minimally Invasive Treatment of Functional Mitral Regurgitation
Recent Patents on Biomedical Engineering (Discontinued) Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study
Current Pharmacogenomics and Personalized Medicine